A pregnant woman with de novo polyuria-polydipsia and elevated liver enzymes. by Barbey, F. et al.
Nephrol Dial Transplant (2003) 18: 2193–2196
DOI: 10.1093/ndt/gfg152
Teaching Point
(Section Editor: K. Ku¨hn)
Supported by an educational grant from
A pregnant woman with de novo polyuria-polydipsia and
elevated liver enzymes
Fre´de´ric Barbey1, Olivier Bonny1, Laura Rothuizen2, Fulgencio Gomez2 and Michel Burnier1
1Department of Nephrology and 2Department of Endocrinology and Diabetology, University Hospital,
Lausanne, Switzerland
Keywords: arginin vasopressin; cysteine-aminopepti-
dase; dDAVP; diabetes insipidus; pregnancy
Case
A 32-year-old black woman, gravida 1, para 0, was
admitted in our hospital in her 29th week of a gemellar
pregnancy because of the risk of preterm delivery and
suspicion of pre-eclampsia. The patient’s pregnancy
had been uneventful until her hospitalization and no
previous history of gestational diabetes or hypertension
was elicited. The patient’s past medical history was
unremarkable. Weight gain during pregnancy had been
appropriate and serial ultrasounds had demonstrated
adequate growth of both fetuses. On admission, she
complained of right abdominal pain but reported no
fever, vaginal bleeding or discharge, headache, blurry
vision or oedema. Physical examination revealed an
afebrile patient with normal skin turgor, and a tender
but not enlarged liver. Her blood pressure was
100/70mmHg, and pulse 80 beats per minute. An
abdominal ultrasound showed a gemellar pregnancy
with normal amniotic ﬂuid, a normal hepatic size and
appearance, and a slight distension of the urinary tract.
The patient was kept under observation. Laboratory
values at entry showed an elevation in liver-function
tests, uric acid and creatinine levels (Table 1).
Haemoglobin, platelet count, coagulation and thyroid
function studies, as well as potassium, calcium and
glycaemia levels were within normal range. HIV as well
as hepatitis serologies were negative. A urine culture
remained sterile. A presumptive diagnosis of acute fatty
liver of pregnancy was made.
From days 2 to 9 of hospitalization, the elevation of
the liver enzymes, and uric acid level persisted, but
without signiﬁcant exacerbation (Table 1). Creatinine
clearance was 99.6ml/min. Maternal blood pressure
and fetal evaluation remained normal. On day 9,
the patient developed a syndrome of polydipsia and
polyuria. These symptoms had been appearing the day
before admission but the patient didn’t mention them
at entry. A ﬁrst recorded urine output was 5.0 l/24 h
with a speciﬁc gravity of 1002. On day 11, urine output
was 8 l, plasma osmolality 290mOsml/kg and urine
osmolality 60. Since glucose, potassium and calcium
levels were normal, a diagnosis of diabetes insipidus
(DI) was retained.
8-D-arginin vasopressin (dDAVP) was not intro-
duced since the course of pregnancy was marked, some
hours later, by a premature rupture of the membranes
with rapid labour initiation. Two healthy female babies
weighing 1630 and 1650 g were delivered vaginally
without complication, at 31 2/7 weeks. The patient
delivered a placenta 1.5 times (640 g) the expected
weight for the gestational age. Post-partum, the patient
nursed her babies normally. On day 13 (1 day after
delivery), the plasma level of arginin vasopressin
(AVP) was 0.6 pg/ml (normal values 0.2–2.5 pg/ml).
Symptoms of polyuria-polydipsia and laboratory
abnormalities regressed rapidly after delivery (Table
1). Plasmatic and urinary osmolality measured 3
months after delivery, with the patient being asymp-
tomatic, were within normal range (Table 1). The ﬁnal
diagnosis was transient DI of the pregnancy, probably
mediated by an excessive activity of placental vaso-
pressinase, and associated with acute fatty liver.
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Discussion
Pregnancy is associated with physiological osmo-
regulatory changes. To explain this well recognized
phenomenon, two mechanisms have been put forward:
a resetting of the osmotic threshold, i.e. the set-point
for plasma osmolality at which pregnant women
experience thirst and release AVP, and the placental
release of a cysteine-aminopeptidase (vasopressinase),
an enzyme that rapidly inactivates AVP. The lowering
of the osmotic threshold leads to a decrease of the
plasma osmolality by 10mOsm/kg at 10 weeks of
pregnancy, after which a new steady state is maintained
until term [1]. Thus, AVP release is not suppressed at
the usual levels of tonicity and free water is retained,
causing a fall in plasma sodium concentration by
5meq/l. Despite the increase in the clearance of AVP
due to vasopressinase effect, AVP plasma concentra-
tions remain unchanged, suggesting a compensatory
increase in secretion to maintain ﬂuid balance.
DI is generally caused either by failure of AVP
secretion (central DI) or by resistance of the renal
collecting duct to AVP (nephrogenic DI). Central DI
may occur secondary to pituitary or brain tumours,
inﬁltrative diseases such as sarcoidosis or histiocytosis,
after trauma, surgery or rupture of intracranial
aneurysm, or be idiopathic [2]. Nephrogenic DI can
be congenital or acquired, linked with chronic
interstitial nephritis, potassium deﬁciency or hypercal-
caemia, or related to drugs [2]. During pregnancy,
and in the absence of glycosuria, hypokalaemia or
hypercalcaemia, DI can be established if a patient with
a syndrome of polyuria-polydipsia has a serum
osmolality >285mOsm/kg associated with persistent
hyposthenuria (Table 2) [1,3]. DI can be conﬁrmed
by a hypertonic saline infusion or a water depriva-
tion test (Table 3). Women with DI will not concen-
trate their urine osmolality, in contrast to women
with psychogenic polydipsia. However, dehydration
is problematic in pregnancy because the resulting
decrease in plasma volume may lead to utero-placental
insufﬁciency [4]. Therefore, a water deprivation test
should be performed only if signs of polyuria or
polydipsia persist more than 6 weeks post-partum.
In pregnant woman, the classical central or
nephrogenic DI should be distinguished from de novo
transient DI (gestational DI), a third category of DI
which appears in late pregnancy and resolves in the very
ﬁrst weeks after delivery, as illustrated in our case
report. On the basis of clinical and physio-pathological
characteristics, at least two forms of gestational DI
should be distinguished [1], apart from a form of DI
appearing early after delivery probably caused by
Sheehan’s syndrome [2]: (i) in patients with previously
unrecognized partial central DI, with sufﬁcient
hormone secretary capacity to escape detection when
non-pregnant, the increased metabolic clearance rate
due to the vasopressinase activity during pregnancy will
lead to DI. This form should be sensitive to AVP. (ii)
The form called transient AVP-resistant DI is due to
excessive degradation of seemingly unaltered secretion
of AVP, due to increase in vasopressinase activity.
Vasopressinase is a cystine aminopeptidase elabo-
rated by placental tissue (trophoblast), which inacti-
vates AVP, oxytocin, and some other small peptides, by
sequentially cleaving amino acids from the N-terminus
[1]. Its physiological function remains however unclear.
Vasopressinase activity increases by 1000-fold from
week 4 to 38 of gestation, remains elevated until
Table 1. Laboratory data
Entry Day 5 Day 11 Day 12 (delivery) Day 14 Day 90
Blood
Na (mmol/l) 141 140 140 139 138
Creatinine (mmol/l) 100 90 101 81 82
BUN (mmol/l) 3.4 3.8
Osmolality (mOsm/kg) 281 290 286
Uric acid (mmol/l) 496 557 514 353
ASAT (U/l) 111 125 120 53
ALAT (U/l) 122 138 116 67
LDH (U/l) 522 555 466
AP (U/l) 218 238 242 201
Bilirubin (mmol/l) <10 <10 <10
Urine
Osmolality (mOsm/kg) 60 136 754
Proteinuria (g/l) 0.02 0.04 0.05
Volume (l/24 h) 8.0 4.4 1.4
ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; LDH, lactate deshydrogenase; AP, total alkaline phosphatases.
Table 2. Major causes of polyuria during pregnancy
Water diuresis Solute diuresis
Primary polydipsia Hyperglycaemia
Central DI Mannitol
Nephrogenic DI Post-obstructive diuresis
Transient DI Saline loading
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delivery, than decreases at a logarithmic rate of 25% a
day post-partum, having virtually no activity by the
12th post-partum day. The release of vasopressinase
results in an 4-fold increase in AVP catabolism rate,
which requires a compensatory synthesis to maintain
AVP plasma concentration and ﬂuid balance
unchanged [1]. Serum vasopressinase activity is
proportional to the weight of the placenta, explaining
that in multiple pregnancies, an increased plasma
vasopressinase activity is encountered [5]. The site of
vasopressinase metabolism is not known, but is likely to
take place in the liver. After delivery and placental
removal, vasopressinase levels decreased rapidly,
resulting in normalization of the ﬂuid balance, and
consequent resolution of the DI.
Administration of AVP can differentiate the two
forms of gestational DI (Table 3) [3]. In central sub-
clinical DI exacerbated during pregnancy, urine should
concentrate within an hour after administration of
AVP i.m., in contrast to transient AVP-resistant DI.
However, most central sub-clinical DI respond only
partially to AVP since part of the exogenous AVP is
degraded by normal levels of vasopressinase. If the
urine still does not concentrate 2 h after AVP
administration, dDAVP, an AVP analogue with a
different N-terminus that renders it resistant to the
vasopressinase action, may be given [6]. Both forms of
transient DI are exquisitely responsive to dDAVP
which constitutes the treatment of choice. In the 17
cases reviewed by Krege et al. [3], only dDAVP
successfully established anti-diuresis. Women with
complete central DI require more exogenous AVP to
control polyuria during pregnancy, probably because
of the increased clearance of AVP due to increased
vasopressinase activity, and present a gradual return of
their usual replacement doses in the post-partum period
[7]. Pre-existing symptomatic central DI should there-
fore be treated with dDAVP during pregnancy. No
adverse maternal or fetal effects from dDAVP use
during pregnancy have been reported [6]. Moreover,
dDAVP has no pressor effect which is important in
view of transient DI associated with pre-eclampsia.
One recent important ﬁnding, in the majority
of women with transient DI of the pregnancy, is
the simultaneous occurrence of anomalies of the
liver-function tests. Krege et al. [3] reviewed reports
of 17 women with transient DI and found associated
abnormal liver tests in 16 of them (in one case liver
functions were not reported). Moreover, they found a
diastolic blood pressure 90mmHg in 12 patients,
proteinuria >250mg/24 h in six of them, and elevated
uric acid levels in 12 cases (not reported in ﬁve). One
woman had recurrence of the DI in a subsequent
pregnancy [3]. In another study, Kennedy et al. [4]
reported six cases of transient DI of the pregnancy in
association with abnormal liver tests and biopsy-
proven acute fatty liver of pregnancy. Five out of six
were primigravida. Elevated blood pressure (>140/
90mmHg), without signiﬁcant proteinuria, was present
in four of them. There was an increase in uric acid levels
(>400 mmol/l) in all but one patient. Three women
have since had uneventful pregnancies. Recently,
Hamai et al. [8] reported six cases of DI during
pregnancy, and observed that pregnancies in which
clinical symptoms of DI became apparent were
associated with hypertension and abnormal biochem-
ical data compatible with pre-eclampsia, whereas
pregnancies preceded by DI were uneventful as long
as dDAVP was appropriately administered.
To explain the association of DI with elevated liver
function tests, one advanced hypothesis is that acute
liver dysfunction could impair degradation of vaso-
pressinase, thereby extending vasopressinase half-life
activity, resulting in greater clearance of AVP. It has
been suspected that pre-eclampsia associated with
excessive vasopressinase activity might be explained if
the products of AVP degradation by vasopressinase
retained pressor activity, even after anti-diuretic
activity has been destroyed. However, Gordge et al.
[9] have shown in a recent study that AVP degradation
products had no signiﬁcant pressor activity and are
therefore unlikely to be pathogenic in hypertensive
pregnancy. An important point is that pregnancies in
women with transient DI should be considered at high
risk because of the potential to develop pre-eclampsia,
or fatty liver. Moreover, the manifestations of DI,
i.e. diluted and abundant urine output, may mask
emerging severe pre-eclampsia.
In our patient, a de novo syndrome of polyuria-
polydipsia associated with hepatic, uric acid, and renal
function abnormalities developed during the third
trimester of pregnancy, while glycaemia, potassium and
Table 3. Water-deprivation, AVP and dDAVP test during pregnancy






Normal >800 >2 Little or no increase Little or no increase
Complete central DI <300 Undetectable Partially or substantially increased Substantially increased
Partial central DI <300–500 <1.5 Partially or substantially increased Substantially increased
Transient AVP-resistant DI <300–500 <1.5 No increase Substantially increased
Nephrogenic DI <300–500 >5 Little or no increase Little or no increase
Primary polydipsia >500 <5 Little or no increase Little or no increase
Modiﬁed from Lanese and Teitelbaum [11].
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calcium levels were in the normal range. It was
characterized by slightly elevated plasmatic osmolality,
hypernatraemia and hyposthenuria. The increase of
uric acid and creatinine plasma levels was attributed to
a probable pre-renal component. Prior to the liver-
function test abnormalities, our patient had neither
hypertension nor proteinuria, excluding the diagnosis
of pre-eclampsia. A toxic, pharmacological, or viral
cause to the elevated liver enzymes was ruled out, and a
diagnosis of fatty liver of pregnancy was at this state the
most probable diagnosis [10]. The rapid amendment of
the symptoms and of laboratory abnormalities after
delivery, was consistent with a transient DI of the
pregnancy. The gemellar nature of the pregnancy that
could induce excessive vasopressinase activity, and the
hepatic dysfunction (acute fatty liver) which could
reduce the catabolism of vasopressinase were consistent
with an AVP-resistant DI of the pregnancy. The normal
plasma AVP level 1 day after delivery (0.6 pg/ml), and
an urinary osmolality spontaneously above 750mOsm/
kg 3 months post-partum render unlikely the diagnosis
of a partial central DI. This case and others previously
reported demonstrate that transient DI appears to be
associated with gemellar pregnancy, pre-eclampsia or
acute fatty liver [3,4,8].
Teaching points
Transient DI of pregnancy can occur in the third
trimester and disappears rapidly post-partum. It is
associated with gemellar pregnancy, pre-eclampsia or
acute fatty liver. There are two distinctive forms—the
central sub-clinical and the AVP-resistant DI. Both
forms respond to dDAVP.
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